Biggest global insulin study progressing well

Fri, 23 Jul 2010
The largest study on insulin therapy ever undertaken has now completed its recruitment process, having enlisted 60,000 patients. The A1chieve(R) project, which spans 28 countries in 4 continents, involves over 3,300 physicians in an observational study to examine the effects of modern insulins in the management of type 2 diabetes .

As a way of copying the natural secretion of insulin in the body, commercial insulin preparations can be used in a variety of ways, depending on each individual's needs, as well as what local practices are for the patient. The study has the task of assessing these different approaches in a real life setting.

The study, organised by healthcare firm Novo Nordisk, will investigate these new insulin regimens, as well as differences in how diabetes is managed by different physicians in different parts of the world. The results of this trans-global study will be available next year.

Philip Home, Chair of the A1chieve(R) Global Advisory Board, said "Once completed A1chieve(R) will provide locally relevant information on the effective use of modern insulins across different regimens. This information could be further useful to inform and improve the local guidelines on the management of type 2 diabetes."

Jesper Hoiland, who is Senior Vice President, Novo Nordisk Region International Operations A/S, added that "The A1chieve(R) study is another major initiative demonstrating our commitment as leaders in the field of diabetes care. Our vast experience and unmatched presence in the emerging countries has enabled us to carry out such a unique and large scale research activity of clinical importance."

Link to this page

Copy and Paste the following HTML into your page.
Share Us
Follow Us